...
首页> 外文期刊>Materials transactions >Development of New Ti-Fe-Ta and Ti-Fe-Ta-Zr System Alloys for Biomedical Applications
【24h】

Development of New Ti-Fe-Ta and Ti-Fe-Ta-Zr System Alloys for Biomedical Applications

机译:用于生物医学的新型Ti-Fe-Ta和Ti-Fe-Ta-Zr系合金的开发

获取原文
获取原文并翻译 | 示例
           

摘要

beta-type titanium alloys consisting of non-toxic elements, Ti-8Fe-STa, Ti-8Fe-8Ta-4Zr, and Ti-10Fe-10Ta-4Zr, were newly designed and developed for biomedical applications. Changes in the mechanical properties of the designed alloys with various heat treatments were discussed on the basis of the resultant microstructures. In addition, the corrosion resistance of the designed alloys was evaluated by polarization test in Hanks' solution. Conventional biomedical titanium and a titanium alloy, cp-Ti and T1-6A1-4V ELI, respectively, were also polarized for comparison. The structural phase of the designed alloys after cold rolling and solution treatment was only the beta phase. The ultimate tensile strength and elongation to fracture of Ti-8Fe-8Ta, Ti-8Fe-8Ta-4Zr, and Ti-10Fe-10Ta-4Zr after solution treatment were 1066MPa and 10 percent, 1051 MPa and 10 percent, and 1092 MPa and 6 percent, respectively. Ti-8Fe-8Ta and Ti-8Fe-8Ta-4Zr have higher strength than conventional biomedical titanium alloys, such as Ti-6Al^lV ELI, Ti-6Al-7Nb, and Ti-13Nb-13Zr. In addition, the elongations to fracture of Ti-8Fe-8Ta and Ti-8Fe-8Ta-4Zr were equal to those of T1-6A1-4V ELI and Ti-6Al-7Nb. The designed alloys and conventional biomedical titanium alloys were spontaneously passivated in Hanks' solution. The current density of cp-Ti and TS-6A1-4V ELI was increased at a potential above 2.5 V. On the other hand, the current density of the designed alloys was abruptly increased at a potential above 3.5 V. This indicated that the designed alloys have an advantage over cp-Ti and Ti-6Al-4V ELI, namely, high resistance to pitting corrosion in biological environments. Therefore, the new beta-type titanium alloys designed in this study, Ti-8Fe-8Ta and Ti-8Fe-8Ta-4Zr, are expected to have good properties as biomaterials.
机译:由无毒元素Ti-8Fe-STa,Ti-8Fe-8Ta-4Zr和Ti-10Fe-10Ta-4Zr组成的新型β型钛合金是为生物医学应用而设计和开发的。在所得的微观结构的基础上,讨论了经过各种热处理的设计合金的机械性能变化。另外,通过在汉克斯溶液中的极化试验评估了设计合金的耐腐蚀性。常规生物医学钛和钛合金分别为cp-Ti和T1-6A1-4V ELI也被极化以进行比较。经过冷轧和固溶处理后,设计合金的结构相仅为β相。固溶处理后的Ti-8Fe-8Ta,Ti-8Fe-8Ta-4Zr和Ti-10Fe-10Ta-4Zr的极限抗拉强度和断裂伸长率为1066MPa和10%,1051 MPa和10%,1092 MPa和分别为6%。 Ti-8Fe-8Ta和Ti-8Fe-8Ta-4Zr具有比常规生物医学钛合金(如Ti-6Al ^ IV ELI,Ti-6Al-7Nb和Ti-13Nb-13Zr)更高的强度。此外,Ti-8Fe-8Ta和Ti-8Fe-8Ta-4Zr的断裂伸长率与T1-6A1-4V ELI和Ti-6Al-7Nb相等。设计的合金和常规的生物医学钛合金在Hanks溶液中自发钝化。在高于2.5 V的电势下cp-Ti和TS-6A1-4V ELI的电流密度增加。另一方面,在高于3.5 V的电势下,所设计合金的电流密度突然增加。合金具有比cp-Ti和Ti-6Al-4V ELI更高的优势,即在生物环境中具有较高的抗点蚀能力。因此,在这项研究中设计的新型β型钛合金Ti-8Fe-8Ta和Ti-8Fe-8Ta-4Zr有望作为生物材料具有良好的性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号